Effect of menopause and different combined estradiol-progestin regimens on basal and growth hormone-releasing hormone-stimulated serum growth hormone, insulin-like growth factor-1, insulin-like growth factor binding protein (IGFBP)-1, and IGFBP-3 levels

Plain-language guide to PMID 9988395 (1999): randomized controlled trial of IGF-1 LR3 and GHRH (Growth Hormone-Releasing Hormone) in 8 women.

Key Facts

PMID: 9988395
Journal: Fertility and sterility
Year: 1999
Study type: Randomized Controlled Trial
Authors: Cano A et al. (3 authors)
DOI: 10.1016/s0015-0282(98)00432-4

What This Study Did, in Plain Language

What Was Tested

This randomized controlled trial looks at IGF-1 LR3 and GHRH (Growth Hormone-Releasing Hormone).

To determine the effects of menopause and three different formulations of E2 plus medroxyprogesterone acetate on serum concentrations of basal and growth hormone-releasing hormone (GHRH)-stimulated growth hormone (GH), insulin-like growth factor-1 (IGF-1), insulin-like growth factor binding protein (IGFBP)-1, IGFBP-3, insulin, and C peptide.

Who Took Part

The abstract describes 8 women taking part.

The age groups tagged for this paper are adults and middle-aged adults, women only.

Menopausal outpatient clinic at an academic tertiary care hospital.

Nineteen postmenopausal women with different menopausal ages.

How the Study Was Run

The design is described as randomized.

Random assignment meant chance, not the researchers, decided who got IGF-1 LR3 and who got the comparison, which limits bias.

Seventeen premenopausal women were included as controls.

Blood samples were collected before treatment and after the completion of each protocol from postmenopausal women, and on cycle days 6-8 from premenopausal women.

What Was Measured

The subject headings attached to it are Basal Metabolism, Estradiol, Growth Hormone-Releasing Hormone, Hormone Replacement Therapy, Human Growth Hormone, Insulin-Like Growth Factor Binding Protein 1 and Insulin-Like Growth Factor Binding Protein 3.

What This Means in Plain Language

The paper is a randomized study of IGF-1 LR3 and GHRH (Growth Hormone-Releasing Hormone) in 8 women.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 1999 (Fertility and sterility), a journal based in United States.

More context: the IGF-1 LR3 compound page and the GHRH (Growth Hormone-Releasing Hormone) compound page, all human trials.

Our Notes on the Compounds

IGF-1 LR3: A modified IGF-1 analog that escapes binding proteins, so it stays active ≥24 h.

GHRH (Growth Hormone-Releasing Hormone): The 44-amino-acid hypothalamic hormone that tells the pituitary to release growth hormone; sermorelin and tesamorelin are analogs.

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.